Credit Suisse AG raised its position in Novavax, Inc. (NASDAQ:NVAX) by 37.1% during the first quarter, Holdings Channel reports. The fund owned 1,519,495 shares of the biopharmaceutical company’s stock after buying an additional 411,371 shares during the period. Credit Suisse AG’s holdings in Novavax were worth $1,945,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of NVAX. Metropolitan Life Insurance Co. NY boosted its position in shares of Novavax by 2.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 203,996 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 5,704 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Novavax by 2.7% in the first quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock worth $440,000 after buying an additional 8,966 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Novavax by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock worth $1,555,000 after buying an additional 10,347 shares during the last quarter. American International Group Inc. boosted its position in shares of Novavax by 7.1% in the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 10,965 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Novavax by 4.2% in the fourth quarter. Teachers Advisors LLC now owns 455,686 shares of the biopharmaceutical company’s stock worth $574,000 after buying an additional 18,519 shares during the last quarter. 50.16% of the stock is owned by institutional investors and hedge funds.

Novavax, Inc. (NVAX) traded down 0.2525% during trading on Thursday, hitting $0.9875. 1,531,132 shares of the company were exchanged. Novavax, Inc. has a 12 month low of $0.73 and a 12 month high of $8.49. The company’s market capitalization is $286.29 million. The stock’s 50-day moving average is $1.16 and its 200-day moving average is $1.15.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The firm had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.15 million. During the same period last year, the business earned ($0.29) earnings per share. Novavax’s revenue was up 168.0% compared to the same quarter last year. Equities research analysts anticipate that Novavax, Inc. will post ($0.62) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/credit-suisse-ag-acquires-411371-shares-of-novavax-inc-nasdaqnvax.html.

A number of equities analysts have commented on the stock. Ladenburg Thalmann Financial Services raised shares of Novavax from a “neutral” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research cut shares of Novavax from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Piper Jaffray Companies reissued a “hold” rating and issued a $1.50 price objective on shares of Novavax in a research note on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $2.00 price objective on shares of Novavax and gave the stock a “hold” rating in a research note on Monday, May 8th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $5.61.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.